• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Study: Rituximab trial for CFS shows promise

Emily

Editor, Senior Moderator
http://www.tv2.no/nyheter/innenriks...reakthrough-can-solve-cfsmystery-3615631.html
English version: Norwegian research breakthrough can solve CFS-mystery

Two oncologists in the city of Bergen in Norway have recently discovered a possible treatment for Chronic Fatigue Syndrome. The drug that they administered improved the condition of two out of three of the patients treated. Several patients were healed.


The results are sensational. Two out of three of the patients experienced major improvement, while some experienced a full recovery


The breakthrough, published today in the medical journal PLOS one, can provide answers to CFS-patients concerning what causes the mysterious disease and how it can be treated.
?We definitely see an effect. There is hope,? states professor and head of oncology at Haukeland University Hospital, Olav Mella to the TV 2 News.

Del p? facebook
TV 2 has exclusive access to the research paper that came out in the medical journal PLOS one. Mella and his colleague, attending MD ?ystein Fluge, have completed a double-blind study on 30 Norwegian CFS-patients.
The results are sensational. Two out of three of the patients experienced major improvement, while some experienced a full recovery.
....


Facts on Rituximab

Rituximab is a chimeric monoclonal antibody that attacks the B cells. The B cells are a form of leucocytes.

Rituximab is used in the treatment of many lymphomas, leukemias and some autoimmune disorders.

Rituximab destroys both normal and malignant B cells that have CD20 on their surfaces, and therefore used to treat diseases which are characterized by having too many B cells, overactive B cells or dysfunctional B cells.

Kilde: Wikipedia/ Md Phd ?ystein Fluge
 
Back
Top Bottom